9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Financial Results, Press Release
Shareholder votes
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Annual Report to Security Holders
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Q2
Q1
FY 2024
Q3
FY 2023
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities
Definitive Revised Proxy Statement
Submission Upload
Correspondence